Biologic Treatments of Psoriasis: An Update for the Clinician

References

• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006
   PubMed Web of Science ®Google Scholar
• Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S2–S6.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627–1632; discussion 1632. doi:10.1001/archderm.139.12.1627
   Google Scholar
• Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9(4):425–437. doi:10.1016/S1474-4422(10)70040-5
   PubMed Web of Science ®Google Scholar
• Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006;54(Suppl 3):S101–S111. doi:10.1016/j.jaad.2005.11.1088
   Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–2022. doi:10.1056/NEJMoa030409
   PubMed Web of Science ®Google Scholar
• Elewski BE, Baker CS, Crowley JJ, et al. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol. 2019;33(11):2168–2178. doi:10.1111/jdv.15793
   PubMed Web of Science ®Google Scholar
• Wu JJ, Abramovits W, Valdecantos WC, et al. 10-year interim results from the ESPRIT registry: real-world safety, effectiveness, and patient-reported outcomes of adalimumab for moderate-to-severe psoriasis. Poster presented at the: 28th European Academy of Dermatology and Venereology (EADV) Congress; October 2019; Madrid, Spain; 2020.
   Google Scholar
• Mahadevan U, Martin CF, Dubinsky M, Kane SV, Sands BE, Sandborn W. 960 exposure to anti-TNFα therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO registry | request PDF. Gastroenterology. 2014. doi:10.1016/S0016-5085(14)60602-8
   Web of Science ®Google Scholar
• Van Der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open. 2018. doi:10.1136/rmdopen-2017-000582
   Web of Science ®Google Scholar
• Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018. doi:10.1016/j.jaad.2018.04.012
   Web of Science ®Google Scholar
• Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017. doi:10.1136/annrheumdis-2017-211384
   Web of Science ®Google Scholar
• Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228–233. doi:10.1136/annrheumdis-2017-212196
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 2003;48(1):68–75. doi:10.1067/mjd.2003.10
   PubMed Web of Science ®Google Scholar
• Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Investig Dermatol. 2004;123(6):1037–1044. doi:10.1111/j.0022-202X.2004.23448.x
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000–1006. doi:10.1136/annrheumdis-2013-204741
   PubMed Web of Science ®Google Scholar
• Kimmel G, Chima M, Kim HJ, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81(3):857–859. doi:10.1016/j.jaad.2019.05.007
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Leonardi C, Wu JJ, et al. One-year pharmacovigilance update of brodalumab. J Drugs Dermatol. 2020;19(8):807–808. doi:10.36849/JDD.2020.5138
   Web of Science ®Google Scholar
• Feldman SR, Wu JJ, Armstrong AW, et al. Evaluating costs of biologic drugs for the treatment of moderate-to-severe psoriasis in the United States. JPPA. 2019;4(3):133–142. doi:10.1177/2475530319842174
   Google Scholar
• Jia X, Zhao Y, Carrico J, et al. Cost-effectiveness of tildrakizumab in U. S. patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;81(4):AB39. doi:10.1016/j.jaad.2019.06.179
   Google Scholar
• Brownstone ND, Reddy V, Thibodeaux Q, et al. Brodalumab for treatment-resistant psoriasis: case reports and safety update. JPPA. 2020;5:82–85. doi:10.1177/2475530320925067
   Google Scholar
• Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016. doi:10.1080/14740338.2016.1221923
   Web of Science ®Google Scholar
• Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77(4):667–674. doi:10.1016/j.jaad.2017.05.033
   PubMed Web of Science ®Google Scholar
• Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2020. doi:10.1111/bjd.19262
   Web of Science ®Google Scholar
• Gottlieb AB, Kubanov A, Doorn MV, et al. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2020;182(4):889–899. doi:10.1111/bjd.18331
   PubMed Web of Science ®Google Scholar
• Bagel J, Nia J, Hashim PW, et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther (Heidelb). 2018;8(4):571–579. doi:10.1007/s13555-018-0265-y
   PubMed Web of Science ®Google Scholar
• Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890–897. doi:10.1136/annrheumdis-2017-212687
   PubMed Web of Science ®Google Scholar
• Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111. doi:10.1186/s13075-019-1882-2
   PubMed Web of Science ®Google Scholar
• Paller AS, Seyger MMB, Magariños GA, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231–241. doi:10.1111/bjd.19147
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Ixekizumab vs. Guselkuamb: 24 week clinical responses and 4-week gene expression data. Oral presentation presented at the: Maui Derm; June 2020; Virtual Congress; 2020.
   Google Scholar
• Smolen JS, Sebba A, Ruderman E, et al. Op0228 efficacy and safety of ixekizumab versus adalimumab (spirit-H2h) with and without concomitant conventional synthetic disease-modifying antirheumatic drugs (dmard) in biologic dmard-naïve patients with psoriatic arthritis: 52-week results. Ann Rheum Dis. 2020;79(Suppl 10):143–144. doi:10.1136/annrheumdis-2020-eular.4615
   Web of Science ®Google Scholar
• Shear NH, Paul C, Blauvelt A, et al. Safety and tolerability of ixekizumab: integrated analysis of injection-site reactions from 11 clinical trials. J Drugs Dermatol. 2018;17(2):200–206.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356. doi:10.1056/NEJMoa1512711
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Chiricozzi A, Ehst BD. Bimekizumab. Curr Derm Rep. 2020;9(1):36–42. doi:10.1007/s13671-020-00286-2
   Web of Science ®Google Scholar
• Reich K, Papp K, Blauvelt A, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis: results from BE VIVID, a 52-week phase 3, randomized, double-blinded, ustekinumab- and placebo‑controlled study. Oral presentation presented at the: American Academy of Dermatology (AAD); March 2020; Virtual Conference; 2020.
   Google Scholar
• Gordon K, Foley P, Krueger JG, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis: results from BE READY, a 56-week phase 3, randomized, double-blinded, placebo-controlled study with randomized withdrawal. Oral presentation presented at the: American Academy of Dermatology (AAD); March 2020; Virtual Conference; 2020
   Google Scholar
• Papp K, Kimball A, Tyring S, et al. Maintenance of treatment response in chronic plaque psoriasis patients continuing treatment or discontinuing treatment with tildrakizumab in a 64-week, randomized controlled, phase 3 trial. J Am Acad Dermatol. 2017;76(6):AB164. doi:10.1016/j.jaad.2017.04.637
   Web of Science ®Google Scholar
• Thaçi D, Iversen L, Pau-Charles I, Rozzo S, Blauvelt A, Reich K. Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were responders at week 28: pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials. Oral presentation presented at the: 27th European Academy of Dermatology and Venereology (EADV) Congress; September 2018; Paris, France; 2018.
   Google Scholar
• Cantrell W, Lee P, Mendelsohn AM, Parno J, Rozzo SJ, Liao W. Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in resurface 1. J Skin. 2020;4(5):s40–s40. doi:10.25251/skin.4.supp.40
   Google Scholar
• Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–586. doi:10.1016/S0140-6736(19)30952-3
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. doi:10.1016/S0140-6736(18)31713-6
   PubMed Web of Science ®Google Scholar
• Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy–assessor-blinded clinical trial. Br J Dermatol. 2020. doi:10.1111/bjd.19341
   Web of Science ®Google Scholar
• Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):1. doi:10.1001/jamadermatol.2020.0723
   PubMed Web of Science ®Google Scholar
• Gordon KB, Bachelez H, Blauvelt A, et al. Pooled long-term safety analysis of risankizumab in patients with moderate to severe psoriasis. Poster presented at the: 78th Annual Meeting of the American Academy of Dermatology; March 2020; Virtual Conference; 2020.
   Google Scholar
• Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. doi:10.1016/j.jaad.2016.11.041
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839. doi:10.1016/S0140-6736(19)31773-8
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431. doi:10.1016/j.jaad.2016.11.042
   PubMed Web of Science ®Google Scholar
• Reich K, Rich P, Maari C, et al. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. Br J Dermatol. 2019;181(1):88–95. doi:10.1111/bjd.17628
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Maari C, Menter MA, et al. Efficacy and safety of mirikizumab in patients with moderate-to-severe plaque psoriasis: 104-week results from a randomized phase 2 study. Poster presented at the: American Academy of Dermatology (AAD); March 2020; Virtual Conference; 2020.
   Google Scholar